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Abstract
The carboxy terminal S-farnesylcysteine of Ras oncoproteins is required for their membrane anchorage and transforming
 .activities. We showed previously that S-farnesylthiosalicylic acid FTS affects the membrane anchorage of activated H-Ras
in EJ cells and inhibits their growth. We report here on structural elements in S-prenyl derivatives that specifically inhibit
the growth of EJ cells, but not of untransformed Rat-1 cells. Inhibition of the Ras-dependent extracellular signal-regulated
 .protein kinase ERK , of DNA synthesis and of EJ cell growth were apparent after treatment with FTS or its 5-fluoro,
5-chloro and 4-fluoro derivatives or with the C S-geranylgeranyl derivative of thiosalicylic acid. The 4-Cl-FTS analogue20
was a weak inhibitor of EJ cell growth. The 3-Cl-FTS analogue and the FTS carboxyl methyl ester were inactive, as were
the C S-geranyl derivative of thiosalicylic acid, farnesol, farnesoic acid, N-acetyl-S-farnesyl-L-cysteine and S-farne-10
sylthiopropionic acid. The structural requirements for anti-Ras activity of S-prenyl analogues thus appear to be rather
stringent. With regard to chain length, the C farnesyl group linked to a rigid backbone seems to be necessary and15
sufficient. A free carboxyl group in an appropriately rigid orientation, as in thiosalicylic acid, is also required. Halogenic
substituents on the benzene ring of the thiosalicylic acid are tolerated only at position 5 or 4. This information may facilitate
the design of potent Ras antagonists and deepen our understanding of the mode of association of Ras with the plasma
membrane. q 1998 Elsevier Science B.V.
Keywords: Ras oncoproteins; Ras-antagonists; Farnesyl analog; Geranylgeranyl analog; EJ cell line
Abbreviations: AFC, N-acetyl-S-farnesyl-L-cysteine; 5-Cl-FTS, S-farnesyl-5-Cl-thiosalicylic acid; 4-Cl-FTS, S-farnesyl-4-Cl-thiosali-
cylic acid; 3-Cl-FTS, S-farnesyl-3-Cl-thiosalicylic acid; DMEM, Dulbecco’s modified Eagle’s medium; DMSO, dimethylsulfoxide; ERK,
extracellular signal-regulated kinase; FCS, fetal calf serum; 5-F-FTS, S-farnesyl-5-fluoro-thiosalicylic acid; 4-F-FTS, S-farnesyl-4-fluoro-
thiosalicylic acid; 3-F-FTS, S-farnesyl-3-fluoro-thiosalicylic acid; FTP, farnesylthiopropionic acid; FTS, S-farnesyl thiosalicylic acid;
FTS-Me, S-farnesyl thiosalicylic acid carboxyl methyl ester; GTS, S-geranyl thiosalicylic acid; GGTS, S-geranylgeranyl thiosalicylic
acid; MAPK, mitogen-activated protein kinase; MBP, myelin basic protein; PPMTase, prenylated protein methyltransferase; SDS-PAGE,
sodium dodecyl sulfate polyacrylamide gel electrophoresis
) Corresponding author. Fax: 972-3-6407643; E-mail: kloog@ccsg.tau.ac.il
0925-4439r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
 .PII S0925-4439 97 00077-X
( )Z. Aharonson et al.rBiochimica et Biophysica Acta 1406 1998 40–50 41
1. Introduction
Ras proteins bind to the inner surface of cell
membranes, where they function as regulators of
w xsignal transduction 1,2 . A variety of cell-surface
receptors associated with cell growth and differentia-
w x  .tion activate Ras 1,2 . The normal wild type forms
of Ras alternate between an inactive GDP-bound
w xstate and an active GTP-bound state 3–5 . Receptor-
induced activation of Ras involves the recruitment of
adaptor proteins and GDPrGTP exchange factors
 .e.g. SOS to the membrane, thereby facilitating di-
rect interaction between the exchange factor and Ras
w x3 . Oncogenic forms of Ras are constitutively active
and therefore transduce growth signals independently
w xof receptors, adaptors or exchange factors 4,5 . How-
ever, like the wild-type Ras, oncogenic forms of Ras
transduce signals downstream only when they dock
w xin the plasma membrane 6–11 . Thus, membrane
anchorage of Ras is required both for receiving up-
stream signals from receptors and for transducing
signals downstream to the Ras effector molecules.
Anchorage of Ras to the membrane is promoted by
at least two structural elements. One of them is the
carboxy terminal farnesylcysteine of Ras, and the
other resides within the adjacent upstream sequences
w xthat vary among the different Ras proteins 10,11 .
Wild-type forms of Ras appear to require the farnesyl
moiety specifically, since geranylgeranylated forms
of non-activated Ras do not behave like the wild-type
farnesylated Ras but rather act as dominant negative
w xmutants 12,13 . Activated forms of Ras, as well as
non-farnesylated, N-myristylated Ras, exhibit growth
w xand transforming activities 12 . However, these Ras
isoforms are not targeted specifically to the plasma
membrane, as are the farnesylated forms of normal
w xand activated Ras proteins 11,12 . It therefore ap-
pears that the farnesyl group in Ras, together with
additional sequences, determine not only membrane
association but also specificity in Ras–membrane
interactions. Such interactions would predict specific
anchorage domains for Ras proteins that recognize
their farnesylcysteine.
Support for a specific Ras-binding domain comes
from recent studies in which wild-type H-Ras was
localized to caveolar membranes in fibroblasts
w x14,15 . Further support comes from our own experi-
ments showing that the farnesyl derivative, S-
 .trans,trans-farnesyl thiosalicylic acid FTS , inter-
feres with the functions of activated H-Ras in Ras-
w xtransformed EJ cells 16,17 . More specifically, FTS
appeared to act as a Ras antagonist that dislodges Ras
from the cell membranes and accelerates its degrada-
w xtion, leading to a decrease in total cellular Ras 18 .
As a result, the Ras-dependent, mitogen-activated
protein kinase cascade Raf-1-MEK-ERK, which is
w xrequired for cell growth and proliferation 1,19–21 ,
w xwas inhibited and EJ cell growth was attenuated 22 .
Specificity of the FTS-induced dislodgment of Ras
was also inferred from the inhibition of ErbB2 trans-
w xformed cells, but not of v-Raf-transformed cells 17 .
Although FTS acts in cell-free systems as an inhibitor
w x16 of the prenylated protein methyltransferase
 .PPMTase which methylates the prenylated cysteine
w xof Ras and of other prenylated proteins 23–25 , its
effects on Ras-transformed cells are not related to
w xRas methylation 17 . That is to say that, FTS does
not inhibit Ras methylation in intact cells at concen-
trations at which it affects Ras membrane anchorage
w xand inhibits cell growth 17 .
The unusual specificity of FTS in inhibiting the
function of activated Ras suggests that its interfer-
ence is confined to Ras interaction with a rather
unique membrane domain. In the present work we
identified the structural elements in S-prenyl deriva-
tives that promote specific interference with the func-
tions of activated Ras. We show that rigid structure,
length of the isoprenoid group, the presence of a free
carboxylic acid and the location of the halogenic
substituents on the benzoic ring of the thiosalicylate
are critically important for the anti-Ras activity of
these compounds.
2. Materials and methods
2.1. Materials
32  .g-P -ATP 3000 Cirmmole was purchased from
 . 3 Rotem Industries Israel . H-Thymidine 6.7
.Cirmmole was from Du-Pont New England Nu-
 .clear. FTS, N-acetyl-S-farnesyl-L-cysteine AFC and
 .farnesylthiopropionic acid FTP were prepared by a
general procedure as described in detail previously
w x16 . The synthetic and analytical data of the new
w xcompounds have been reported elsewhere 26 , and
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Table 1
Chemical structure of S-prenyl derivatives of thiosalicylic acid
their chemical structures are shown in Table 1. They
are S-trans,trans-farnesyl-5-chloro thiosalicylic acid
 .  . 5-Cl-FTS and its 4-chloro 4-Cl-FTS , 3-chloro 3-
.  .  .Cl-FTS , 5-fluoro 5-F-FTS and 4-fluoro 4-F-FTS
 .derivatives, the FTS carboxyl methyl ester FTS-Me ,
 .S-trans-geranyl thiosalicylic acid GTS , and S-all
 .trans-geranylgeranyl thiosalicylic acid GGTS . Anti-
ERK-2 Ab were from Santa Cruz. Protein A sepharose
 .and myelin basic protein MBP were from Sigma.
All other chemicals were from Merck or Sigma. Gel
electrophoresis supplies were from Bio-Rad and tis-
sue culture supplies were from Biological Industries,
 .Beit Haemek Israel . Farnesol and farnesoic acid
were a gift from Dr. Cary Weinberger.
2.2. Methods
2.2.1. Cell culture procedures
EJ or Rat-1 cells were grown in Dulbecco"s modi-
 .fied Eagle’s medium DMEM r10% fetal calf serum
 .FCS at 378C, in a humidified atmosphere of 95%
airr5% CO . To estimate the effects of FTS and its2
analogues on cell growth, cells were plated at a
density of 2=103 cells per well in 24-well plates, to
 . which either 0.1% dimethylsulfoxide DMSO con-
.trol or the indicated concentrations of the analogue
were added after 24 h. Solutions of the compounds
were freshly prepared for each experiment in 100%
DMSO, and diluted with DMEMr10% FCS to yield
a 100= drug solution containing 10% DMSO. The
 .stock solutions 10 ml were added directly to the
wells. The cells were grown for 5 days, detached and
counted.
([ ])2.2.2. Determination of ERK acti˝ity 27
EJ cells were plated at a density of 1=106 cellsr6
cm dish in DMEMr10% FCS. One day after plating,
 .the indicated S-prenyl derivative 25mM or 0.1%
 .DMSO control was added to the medium for 24 h.
ERK activity was then determined in cell lysates. The
experimental dishes were placed on ice and the cells
were washed twice with cold PBS. To each dish was
added 1 ml of ERK lysis buffer 50 mM b-glycero-
phosphate, 1.5 mM EGTA, 2 mM sodium orthovana-
date, 1 mM dithiothreitol, 2 mgrml leupeptin,
2 mgrml aprotinin, 1 mM benzamidine and 1% NP-
.40 , and the dishes were kept on ice for 10 min. The
cell lysates were collected into Eppendorf tubes, vor-
texed, and centrifuged at 10,000=g for 10 min at
48C. The supernatants were collected and incubated
for 2 h at 48C with 5 ml of anti-ERK-2 Ab Santa
. Cruz and 30 ml of protein A-sepharose beads di-
.luted 1:1 in ERK lysis buffer . The supernatant was
discarded and the beads were washed three times
with ERK lysis buffer, then twice with kinase buffer
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30 mM Tris–HCl pH 8.0, 20 mM MnCl and 2 mM2
.MgCl . Following incubation of the beads for 30 min2
at 378C, 30 ml of complete kinase buffer containing
the above kinase buffer and 15mg MBP, 10 mM ATP
32 .and 5 mCi g P-ATP were added to each sample.
The reaction was stopped by the addition of 6 ml of
6= Laemmli sample buffer and heating for 5 min at
958C. Following a short spin, the supernatant was
collected and the proteins separated by sodium dode-
cyl sulfate polyacrylamide gel electrophoresis SDS-
.PAGE; 15% acrylamide on mini-gels. Phosphory-
lated MBP was visualized by autoradiography of the
dried gels on X-ray films and quantified by densito-
metric analysis.
w3 xH -Thymidine incorporation into DNA. EJ cells
were plated at a density of 104 cells per well and
grown for 24 h in DMEMr10% FCS in 24-well
plates. The medium was then replaced by
DMEMr0.75% FCS. Following incubation for 24 h,
10% FCS was added to the cells in the presence of
 .the indicated S-prenyl derivative 5–50 mM or 0.1%
 .DMSO control . Drugs were introduced 30 min prior
to FCS addition. The cells were then incubated for
w3 x  .2 h, after which H -thymidine 1 mCirml was added
and incubation was continued for a further 3 h. Incor-
w3 xporation of H -thymidine into DNA was measured
 .in 2% trichloroacetic acid TCA precipitates, as
w xpreviously described 28 .
3. Results
To determine which structural elements in S-pre-
nyl derivatives of thiosalicylic acid promote interfer-
ence with functions of activated Ras, we used ana-
logues with different halogenic substituents on the
benzene ring, analogues with different lengths of the
prenyl chain, and the carboxyl methyl ester of FTS
Fig. 1. Typical photomicrographs of EJ cells grown in the absence and in the presence of S-farnesyl derivatives. Cells were plated at a
6  .density of 1.5=10 cells per 10-cm plate and grown for 5 days in the presence of the solvent control or the indicated derivatives, as
 .detailed in Section 2, then photomicrographed magnification 100= .
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Fig. 2. Dose-dependent inhibition of EJ cell growth by 5-Cl-FTS. Cells were plated and treated with 5-Cl-FTS as described for Fig. 1.
 .Typical photomicrographs magnification 100= are shown.
 .FTS-Me . The structures of these compounds are
shown in Table 1. They include chloro and fluoro
 .derivatives of FTS e.g., 5-Cl-FTS and 5-F-FTS , and
 .  .the C GTS and C GGTS S-prenyl analogues.10 20
Initial experiments indicated that some of these
compounds, but not all, could inhibit the growth of
H-Ras-transformed EJ cells. Trypan blue staining
indicated that cell death in the presence of 50 mM of
each of the compounds was similar to that observed
 .in controls 5–10% . Among the active compounds
were 5-Cl-FTS and 5-F-FTS. Typical photomicro-
graphs of a control EJ cell culture and of EJ cell
cultures grown for 5 days in the presence of 25mM
 .FTS, 25mM 5-Cl-FTS or 25mM 5-F-FTS Fig. 1
demonstrate the growth-inhibitory effects of these
compounds. As shown, cultures grown in the pres-
ence of each of the compounds had fewer and smaller
foci than control cultures. Photomicrographs of EJ
cells treated with various concentrations of 5-Cl-FTS
Fig. 3. Inhibition of EJ but not of Rat-1 cell growth by S-farnesyl
derivatives. Cells were grown in the presence of 0.1% DMSO
 .  .control or the indicated S-farnesyl derivative 25mM for 5
days, and were then counted as described in Section 2. Data
 .means of triplicates " SD are expressed as the ratio between
the numbers of cells in the drug-treated cultures and in the
solvent-treated control cultures.
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Fig. 4. Dose-response curves for the inhibition of EJ cells by various S-prenyl derivatives. Cells were plated at a density of 2=103 cells
per well in 24-well plates and grown for 5 days in the presence of the indicated concentrations of each derivative, then counted. Assays
were performed in triplicate and the data are presented as the ratio between the numbers of cells in drug-treated cultures and in the
solvent-treated control cultures. Data represent the means of triplicate samples whose SD values did not exceed those given in Fig. 3. Left
 .  .  .  .panel - dose-response curves for 5-Cl-FTS l , 4-Cl-FTS B and 3-Cl-FTS D . Middle panel - dose-response curves for 5-F-FTS l ,
 .  .  .  .  .4-F-FTS B and FTS-Me D . Right panel - dose-response curves for FTS l , GGTS B and GTS D .
 .Fig. 2 demonstrate the dose dependency of the
inhibitory effect of 5-Cl-FTS, where the decrease in
the number of foci and in cell-number is observed.
The growth of untransformed Rat-1 cells, unlike
that of EJ cells, was not inhibited by any of the active
S-prenyl derivatives; as an example, a comparison
Table 2
Estimated inhibitory potencies of S-prenyl derivatives
Inhibition of EJ cell Inhibition of ERK activity Inhibition of DNA
ba c .  .  .growth IC , mM in EJ cells % synthesis in EJ cells IC , mM50 50
FTS 5–15 70–80 7.5–12
5-F-FTS 10–26 50–60 9–21
5-Cl-FTS 13–22 50 9–19
4-F-FTS 15–30 70–80 ND
4-Cl-FTS 42–50 y 45–50
3-Cl-FTS )50 0.0 )50
FTS-Me )50 y )50
GTS )50 0.0 y
GGTS 20–36 40.0 y
AFC )50 y y
FTP )50 y y
Farnesyl )50 y
Farnesoic acid )50 y y
Thiosalicylic acid )50 y y
IC values represent drug concentrations that yield 50% inhibition of the measured parameters in each assay, as described in Section 2.50
The lowest and the highest values recorded in 2–3 separate experiments are given.
a EJ cell growth was determined by direct counting of cells grown for 5 days in the presence of various drug concentrations, as detailed in
Fig. 4.
b ERK was immunoprecipitated from lysates of cells grown in the presence of 25mM of each compound, and activity was determined
using MBP as a substrate, as detailed in Fig. 5. The extent of MBP phosphorylation was estimated densitometrically, and percent
inhibition was then calculated. The lowest and the highest values recorded in 2–3 experiments are given.
c w3 xDNA synthesis was estiamted by measuring the incorporation of H -thymidine into DNA in EJ cells simulated by serum in the
presence of various drug concentrations, as detailed in Fig. 6.
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between the effects of FTS, 5-Cl-FTS and 5-F-FTS
on the growth of EJ and Rat-1 cells is shown in Fig.
3.
To obtain a quantitative estimate of the growth-in-
hibitory potencies of the different S-prenyl deriva-
tives, EJ cells were grown for 5 days in the absence
and in the presence of various concentrations of each
compound, then detached from the plates and counted.
Results of typical experiments are shown in Fig. 4.
Among the chloro derivatives, 5-Cl-FTS exhibited
 .the highest inhibitory activity IC 13–22 mM , and50
 .4-Cl-FTS was less potent IC 42–50 mM . 3-Cl-FTS50
was almost inactive, inducing only 20% inhibition of
EJ cell growth even at a concentration of 50 mM
  ..Fig. 4 A . The fluoro derivatives, 5-F-FTS and
  ..4-F-FTS, were equipotent Fig. 4 B . These deriva-
tives and 5-Cl-FTS appeared to be only 1.5- to 2-fold
 .less active than FTS Fig. 4, Table 2 . These results
suggest that halogenic substitutions at position 5 of
the benzene ring of thiosalicylic acid do not lead to
loss of inhibitory activity. Substitution at position 4
was tolerated only with fluor, the relatively smaller
halogen, and substitution at position 3 resulted in loss
of activity.
The carboxyl methyl ester of FTS did not inhibit
  ..the growth of EJ cells even at 25mM Fig. 4 B . It
 .had a small inhibitory effect 20% only at a concen-
tration of 50 mM. This finding points to the impor-
tance of the free carboxyl group of FTS in ensuring
inhibitory activity. Another important factor for in-
hibitory activity appears to be the length of the
isoprenoid group, as indicated by the lack of inhibi-
tion of EJ cell growth by the C prenyl derivative10
  ..GTS Fig. 4 C , whereas growth was inhibited by
the C prenyl analogue GGTS. At relatively low20
 .concentrations -5mM the latter appeared to be as
active as FTS, and at higher concentrations )
.10 mM its inhibitory activity was somewhat lower
  ..than that of FTS Fig. 4 C . Thus, with regard to
chain length the C farnesyl group of FTS appears15
to be necessary and sufficient for its growth-inhibi-
tory effects in EJ cells.
We also examined the effects of the farnesoids
farnesol and farnesoic acid, as well as of thiosalicylic
acid and farnesyl derivatives of non-rigid carboxylic
 .acids AFC and FTP , on EJ cell growth. None of
these compounds exhibited inhibitory activity at con-
 .centrations of up to 50 mM Table 2 .
Next we examined whether the observed growth
inhibition of Ras-transformed cells by the different
S-prenyl analogues is due to interference with a
major Ras-dependent mitogen-activated protein ki-
 .nase MAPK , namely ERK, which is required for
cell growth and transformation in Ras-transformed
w xfibroblasts 21,27 . EJ cells were exposed to FTS,
3-Cl-FTS, 5-Cl-FTS, 5-F-FTS, 4-F-FTS, GTS or
GGTS for 24 h. ERK was then immunoprecipitated
from the cell lysates and the kinase activity was
w xmeasured using MBP as a substrate 27 . Fig. 5
shows typical results of these experiments. In agree-
w xment with recent studies 22 , FTS inhibited the
activity of ERK in EJ cells. 5-Cl-FTS, 5-F-FTS,
4-F-FTS and GGTS similarly inhibited ERK activity
 . Fig. 5 , but 3-Cl-FTS and GTS had no effect Fig.
.5 . The apparent potencies of these compounds in
inhibiting ERK activity appears to correlate with their
growth-inhibitory potencies. These results suggest that
the more active inhibitors of EJ cell growth, but not
the inactive compounds, affect Ras-dependent signal-
ing to ERK.
Fig. 5. Interruption of ERK activity in EJ cells by S-prenyl
derivatives. EJ cells were plated and treated for 24h with the
 .indicated S-prenyl derivative 25mM . ERK activity was deter-
mined in the cell lysates with MBP as substrate, as described in
Section 2. The phosphorylated MBP bands detected by auto-
 .radiography are shown for control C, 0.1% DMSO , FTS,
3-Cl-FTS, 5-Cl-FTS, 4-F-FTS and 5-F-FTS upper, experiment
. a1 and for control, FTS, GTS and GGTS lower, experiment
.a2 .
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w3 xFig. 6. Inhibition of H -thymidine incorporation into DNA by various S-prenyl derivatives. EJ cells were grown for 24 h in
 .DMEMr0.75% FCS and then stimulated by 10% FCS with or without control the indicated concentrations of the S-prenyl derivative.
w3 xH -thymidine was added after 2 h and its incorporation into DNA was determined 3 h later, as described in Section 2. Assays were
w3 xperformed in triplicate and the data are presented in terms of H -thymidine incorporation in drug-treated cells as a percentage of control.
Data represent the means of triplicate samples whose SD values were less than 10%.
Activation of ERK in fibroblasts leads to an in-
crease in DNA synthesis and cell multiplication
w x19,20 . We therefore examined whether the S-prenyl
derivatives of thiosalicylic acid can inhibit DNA
synthesis in EJ cells, by measuring their effects on
w3 xthe incorporation of H -thymidine into DNA. Re-
 .sults of a typical experiment shown in Fig. 6 indi-
cated that, like FTS, the more active compounds
5-Cl-FTS and 5-F-FTS exerted dose-dependent inhi-
w3 xbition of the serum-stimulated incorporation of H -
thymidine into DNA in EJ cells. For both of these
compounds, the estimated IC values were 9–20 mM.50
4-Cl-FTS was less potent and FTS-Me had no activ-
 .ity Fig. 6 . The estimated potencies of the different
S-prenyl analogues in inhibiting DNA synthesis thus
seem to correlate well with their inhibition of EJ cell
 .growth Table 2 .
4. Discussion
In this study we identified structural elements in
S-prenyl derivatives that promote interference with
functions of activated Ras in EJ cells. First, simple
farnesoids such as farnesol or farnesoic acid had no
effect on EJ cell growth. Second, S-farnesyl ana-
logues of non-rigid carboxylic acid derivatives, such
as N-acetyl-S-farnesylcysteine and S-farne-
sylthiopropionic acid, also did not inhibit EJ cell
growth. Together these findings indicate that the C15
farnesyl group, by itself and even when thioether-lin-
ked to a flexible backbone, is not sufficient for
anti-Ras activity. They also support our earlier sug-
gestion that rigid carboxylic acids may provide an
appropriate structural backbone for anti-Ras activity
w xof S-prenyl derivatives 16 . Third, the free carboxyl
group of FTS appears to be required for inhibition of
EJ cell growth, as shown by the lack of growth-in-
hibitory activity of FTS-Me. Fourth, the length of the
isoprenoid groups is also important. The C farnesyl15
of FTS is critical for inhibition of EJ cell growth, as
shown by the lack of inhibitory activity of the C10
geranyl derivative GTS. The C geranylgeranyl ana-20
logue GGTS exhibited inhibitory activity comparable
to that of FTS. Together these findings suggest that
for isoprenoid groups linked to a rigid backbone, a
length of the C is necessary and sufficient for15
inhibition of EJ cell growth.
Finally, activity can be affected by the nature and
locality of substituents on the benzene ring of the
FTS analogue.The relatively large chloro substituent
at position 4 or 3 does not support activity as shown
by loss of the growth-inhibitory activity of 4-Cl-FTS
and 3-Cl-FTS. Halogenic substituents at position 5,
as in 5-Cl-FTS and 5-F-FTS, are tolerated, as shown
by the fact that these compounds were only 1.5- to
2-fold less potent than FTS. The relatively small
fluoro substituent was tolerated at position 4 as well.
These findings, and the loss of anti-Ras activity in the
q w x5-N H derivative of FTS 16 , may suggest an3
additional structural requirement for growth-inhibi-
tory activity of these analogues, namely, a protonated
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carboxylic group. This is because the predicted order
of acidity of the carboxylic group in the benzoic ring
of the 5-substituted analogues is inversely related to
their potency. Whereas the electron-withdrawing ef-
w xfects 29 of the 5-substituents are in the rank order of
NqH )Cl)F)H, the rank order for inhibition of3
 .EJ cell growth is FTS H )5-F-FTS)5-Cl-FTS)
5-NqH -FTS. Taken together, our results show that3
the structural requirements for the inhibition of EJ
cell growth by S-prenyl analogues are rather strin-
gent. It appears that for this activity an S-farnesyl
 .group, and a free probably protonated carboxyl
group in an appropriately rigid orientation are pre-
ferred. The lack of FTS-Me activity may be rather
surprising given that the carboxy terminal farnesyl-
cysteine of Ras proteins is carboxyl methylated
w x17,23,25 . One should point out, however, that meth-
ylation of Ras is not required for Ras membrane
w xanchorage and transforming activity 7,11 . It is also
worth noting that Ras methylation may be reversed
w xby methylesterases 25 . Perhaps methylated and un-
methylated Ras associate differently with the plasma
membrane where the unmethylated form interacts
with domains that are recognized by FTS, but not by
its carboxyl methylated form.
Significantly, none of the active compounds could
inhibit the growth of untransformed Rat-1 cells. This
indicates that these compounds display selectivity
towards EJ cells, which – unlike Rat-1 cells – ex-
press an activated H-Ras protein. Our results showing
that the more active analogues that inhibited EJ cell
 .growth but not the inactive analogues also inter-
rupted ERK activation and DNA synthesis strongly
w xsuggested that these compounds, like FTS 17,18 ,
affect the activated H-Ras in EJ cells. Preliminary
results indeed showed that 5-Cl-FTS, 5-F-FTS and
GGTS, but not 3-Cl-FTS or FTS-Me, dislodge Ras
from EJ cell membranes; this pattern of potency is
retained in a cell free system unpublished observa-
.tions , suggesting that it is not only due to differences
in the ability of the various compounds to penetrate
the cell membrane. In view of the similar rank of
order of their potency in the growth inhibition assays,
it is likely that varied membrane penetration is not
the major cause for the observed differences. We can
not rule out, however, possible differences in rates of
membrane penetration of the various compounds. If
such differences exist they may explain, for example,
why 4-Cl-FTS exhibited a higher potency in the
5-day cell-growth assay compared to its potency in
the 24 h DNA synthesis assay.
Other, yet unknown, factors may also contribute to
differences in structure activity relationships of the
compounds in the distinct assays used here. It is
possible that some of the compounds can affect not
only Ras membrane localization but also interfere
with functions of other prenylated proteins associated
with cell growth and transformation, e.g. Rac and
w xRho 30 . Such effects can, for example, explain how
a compound such as 5-Cl-FTS, that was less active
than FTS or 5-F-FTS in inhibiting ERK activity,
showed relatively high potency in inhibiting EJ cell
growth.
Whatever the explanation, it appears that S-prenyl
derivatives of thiosalicylic acid can interfere with
Ras-membrane interactions and that distinctive struc-
tural elements are required for expression of this
inhibitory activity. Interestingly, previous studies have
revealed other structural requirements in S-prenyl
derivatives for their interactions with protein andror
lipid environments that are not related to membrane
domains with which Ras proteins associate. One in-
teresting example of such structural requirements is
given by farnesylcysteine00 analogues that stimulate
the intrinsic ATPase activity of the multidrug-re-
w xsistant P-glycoprotein 31 . Only analogues with a
free amino group, a carboxyl methyl ester and either
an S-farnesyl or an S-geranylgeranyl group were
w xfound to activate P-glycoprotein activity 31 . These
specific structural requirements differ from those de-
scribed here for anti-Ras activity of S-prenyl deriva-
tives. Other examples are provided by the effects of a
variety of N-substituted farnesylcysteine analogues
on platelet aggregation and on receptor-mediated su-
w xperoxide formation in neutrophils 32 . Those studies
demonstrated that the type of the N-substituent deter-
mines whether or not such compounds can activate or
inhibit the biological functions in these systems. They
also demonstrated that certain derivatives, e.g. N-
pivolyl farnesylcysteine, can block platelet aggrega-
tion but do not interact with PPMTase, the enzyme
w xthat methylates prenylated proteins 32 . It therefore
appears that the structural elements in farnesylcys-
teine analogues required for inhibition of platelet
aggregation differ from those required for interac-
tions with PPMTase. We also show an analogous
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lack of correlation in that compounds which act as
w xPPMTase substrates, such as AFC and FTP 33–35 ,
do not act as Ras antagonists. Some of the S-pre-
nylated rigid carboxylic acid derivatives described
here and elsewhere act as inhibitors of the PPMTase
w xin cell-free systems 16,26 . From previous studies
we know, however, that even the most potent antago-
nist in this group of compounds, namely FTS, does
not inhibit Ras methylation in intact EJ cells at the
 .concentration range 5–25mM at which it inhibits
w xtheir growth 17 . Also, methylation of activated Ras
is not required for its growth and transforming activi-
w xties 7 . It follows that the anti-Ras activity of FTS
and its active analogues is unrelated to the inhibition
of PPMTase.
The stringent structural requirements for the anti-
Ras activity of S-prenyl derivatives may be rather
surprising in light of the knowledge of lipid modifica-
tions that promote membrane anchorage and trans-
forming activity of Ras isoforms. Such isoforms can
tolerate, for example, geranylgeranyl or N-myristyl
w xmodifications 12 . Because all Ras isoforms are nor-
w xmally farnesylated 10–12 , and since FTS dislodges
the activated H-Ras in a rather specific manner from
w xEJ cell membranes 17,18 , we think that the domains
with which FTS interacts are those that recognize
activated farnesylated Ras. This would imply that
FTS would not interfere, for example, with the func-
tion of activated N-myristyl Ras proteins and that
different Ras isoforms would exhibit different modes
of interaction with the plasma membrane.
Several lines of evidence appear to be consistent
with this prediction. We know from our own experi-
ments that FTS is significantly more potent in dis-
lodging activated H-Ras from EJ cell membranes
than in dislodging the normal forms of Ras from
w xRat-1 cell membranes 18 . This suggests that the
normal forms of Ras bind more avidly than the
oncogenic forms of Ras to the plasma membrane.
Furthermore, we found that FTS and 5-Cl-FTS have
 .only a small effect -15% inhibition on the growth
w xof N-myristyl H-Ras-transformed Rat-1 cells 18 . In
addition to these results, recent studies appear to
indicate that Ras proteins may indeed display differ-
ent modes of membrane association. For example,
normal H-Ras has been localized to caveolar mem-
w xbranes in fibroblasts 14,15 , where Ras-GDP but not
w xRas-GTP binds caveolin 36 . Other experiments have
demonstrated that caveolae are absent and caveolin
levels markedly reduced in H-Ras transformed
w xNIH3T3 cells 36 .
Our results demonstrating that FTS, but not GTS
or FTS-Me, affects the function of activated Ras
appear to define specificity towards membrane do-
mains with which farnesylated oncogenic Ras pro-
teins are associated. The nature and locality of such
domains is not yet known. They could reside within
the lipid bilayer andror within membrane-anchored
proteins. Since Ras is localized to the inner surface of
the plasma membrane, such domains might be com-
posed of lipids and proteins of the inner leaflet of the
plasma membrane. Whether or not this is the reason
why FTS, but not GTS or FTS-Me, acts as a Ras
antagonist must be examined in detail in cell-free
systems in order to examine directly the effects of
these and other compounds on Ras membrane an-
chorage. The results presented here enable the design
of experiments along these lines. Such experiments
should provide new insights into membrane domains
that associate Ras isoforms and which are therefore
likely to be important targets for anti-cancer drugs.
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